Human Immunodeficiency Virus–Associated Lung Malignancies

Lambert, Allison; Merlo, Christian A.; Kirk, Gregory D.

doi:10.1016/j.ccm.2013.01.008

Cited by 20 publications

(11 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 In HIV-uninfected smokers, low-dose CT screening reduced lung cancer mortality. 56 In view of the high smoking prevalence 30,31 and lung cancer risk in HIV-infected patients, this population is expected to have an increased need for screening CT in the near future.…”

Section: Lung Cancer Screening In Smokers Infected With Hivmentioning

confidence: 99%

“…4 Subsequent to the rise in life expectancy, the risk of age-associated chronic diseases (eg, cardio vascular, metabolic, renal, neurological) and non-AIDS defining malignancies is increasing in HIV-infected individuals. 2,4–7 The prevalence of multiple morbidities in HIV-infected individuals is 65%, 8 with lower nadir CD4 cell count and higher viral load associated with greater multimorbidity. 9 Data suggest an increased prevalence of obstructive lung diseases in HIV-infected individuals, including both asthma and chronic obstructive pulmonary disease (COPD).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HIV-associated obstructive lung diseases: insights and implications for the clinician

Drummond¹,

Kirk²

2014

The Lancet Respiratory Medicine

View full text Add to dashboard Cite

The effectiveness of antiretroviral therapy to control HIV infection has led to the emergence of an older HIV population who are at risk of chronic diseases. Through a comprehensive search of major databases, this Review summarises information about the associations between chronic obstructive pulmonary disease (COPD), asthma, and HIV infection. Asthma and COPD are more prevalent in HIV-infected populations; 16–20% of individuals with HIV infection have asthma or COPD, and poorly controlled HIV infection worsens spirometric and diffusing capacity measurements, and accelerates lung function decline by about 55–75 mL/year. Up to 21% of HIV-infected individuals have obstructive ventilatory defects and reduced diffusing capacity is seen in more than 50% of HIV-infected populations. Specific pharmacotherapy considerations are needed to care for HIV-infected populations with asthma or COPD–protease inhibitor regimens to treat HIV (such as ritonavir) can result in systemic accumulation of inhaled corticosteroids and might increase pneumonia risk, exacerbating the toxicity of this therapy. Therefore, it is essential for clinicians to have a heightened awareness of the increased risk and manifestations of obstructive lung diseases in HIV-infected patients and specific therapeutic considerations to care for this population. Screening spirometry and tests of diffusing capacity might be beneficial in HIV-infected people with a history of smoking or respiratory symptoms.

show abstract

Section: Lung Cancer Screening In Smokers Infected With Hivmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

HIV-associated obstructive lung diseases: insights and implications for the clinician

Drummond¹,

Kirk²

2014

The Lancet Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…However, given the number of patients who live with chronic HIV infection globally (approximately 30 million), HIV associated pulmonary hypertension will become an important issue in the coming years. (75, 76) Pulmonary malignancies (77), interstitial lung disease (78), obstructive airway disease and emphysema (79), and bronchiectasis (80) are other pulmonary disorders which are frequently seen in HIV infected population. Immunogenicity and safety of conjugated pneumococcal vaccine have been demonstrated.…”

Section: Pcv13 For Patients With Pulmonary Diseasesmentioning

confidence: 99%

Pneumococcal Vaccine and Patients with Pulmonary Diseases

Mirsaeidi

Ebrahimi

Allen

et al. 2014

The American Journal of Medicine

View full text Add to dashboard Cite

Chronic pulmonary diseases describe chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (e.g., methotrexate, anti-TNF inhibitors), having concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS), nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine 23-valent (PPSV23).

show abstract

“…El CP es la tercera neoplasia más frecuente en los pacientes con infección por el VIH, solamente superada por los TDS 16 .…”

Section: Cáncer De Pulmónunclassified

Guía de práctica clínica sobre los tumores no definitorios de sida e infección por el virus de la inmunodeficiencia humana

Santos¹,

Valencia²

2014

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Human Immunodeficiency Virus–Associated Lung Malignancies

Cited by 20 publications

References 113 publications

HIV-associated obstructive lung diseases: insights and implications for the clinician

HIV-associated obstructive lung diseases: insights and implications for the clinician

Pneumococcal Vaccine and Patients with Pulmonary Diseases

Guía de práctica clínica sobre los tumores no definitorios de sida e infección por el virus de la inmunodeficiencia humana

Contact Info

Product

Resources

About